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ABSTRACT
Introduction: Magnetic resonance imaging
(MRI) is increasingly used in patients with
rheumatoid arthritis (RA) to determine residual
inflammation after treatment and as a predictor
of structural damage progression. Establishing
an optimal threshold of inflammatory activity
that predicts lower risk of structural damage
progression may inform treatment decisions.
This post hoc analysis investigated whether
patients with RA at low risk of structural dam-
age progression can be identified based on MRI
inflammation thresholds.
Methods: Hand and wrist MRI was performed
at baseline, and at months 6 and 12 in a phase
3b, randomized, active-controlled, double-blind
trial of abatacept in early RA (AVERT).
Pathologies were scored using the OMERACT
RA MRI Score. Data were stratified into two risk
subgroups (less and more severe inflammation)
for structural damage progression (erosion
change[0.5) based on baseline inflammation.
In this post hoc analysis, log odds ratios of
probability of progression {adjusted for baseline
Disease Activity Score in 28 joints [C-reactive
protein; DAS28 (CRP)]} were compared between
subgroups to test the performance of inflam-
mation thresholds.
Results: There were 351 randomized and trea-
ted patients with baseline MRIs, of whom 276
(78.6%) and 235 (67.0%) had MRIs available at
months 6 and 12, respectively. The DAS28
(CRP)-adjusted probabilities of progression from
baseline to month 12 based on scores at base-
line, and from months 6 to 12 based on month
6 scores, were significantly lower among
patients with less inflammation
(P\0.0001–0.0459), independent of clinical
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disease activity. Predefined thresholds of syn-
ovitis B 3 (total score 21), osteitis B 3 (total
score 69) and total inflammation score (osteitis
double-weighted) B 9 were associated with a
lower likelihood of structural damage progres-
sion in unadjusted analyses.
Conclusion: Levels of MRI-determined inflam-
matory activity below defined thresholds were
independently associated with a lower risk of
structural damage progression in early RA, pro-
viding a potential trial endpoint for levels of
inflammation not associated with progression.
Trial Registration: ClinicalTrials.gov identifier,
NCT01142726.
Funding: Bristol-Myers Squibb.
Keywords: Biological therapies; DMARDs;
Inflammation; Magnetic resonance imaging;
Rheumatoid arthritis; Rhuematology
INTRODUCTION
The concept of treat-to-target is now well
established in the management of rheumatoid
arthritis (RA), with clinical targets aimed at low
disease activity or remission [1]. Modern imag-
ing, including magnetic resonance imaging
(MRI) and ultrasonography, is increasingly used
to accurately determine residual inflammation
after treatment, as imaging-detected inflamma-
tion can predict structural damage progression
[2–6]. However, there is little information on
how low inflammatory activity must be on
imaging in order to be confident that progres-
sion will not occur [5]. Additionally, treating
physicians face a challenge when determining
to what extent inflammation can be managed
with symptomatic treatments alone or when
more potent agents, such as biologic disease-
modifying antirheumatic drugs (DMARDs), are
required.
A previous study suggested levels of synovi-
tis, osteitis and a combined total inflammation
score correlated with the risk of structural
damage progression independent of clinical
disease activity [7]. Validation of these levels
would provide physicians with clinically rele-
vant, imaging-detected inflammation targets.
Establishing a threshold of inflammatory
activity that predicts a lower risk of structural
damage progression would help to avoid
unnecessary initiation, premature tapering or
other changes to treatment, as well as inform
the physician on whether a review of treatment
was needed. The aim of this post hoc analysis
was to examine the outcomes of patients with
early RA participating in a large clinical trial,
based on their degree of MRI-determined syn-
ovitis, osteitis and combined total inflamma-
tory activity, and to validate the
aforementioned approach as a predictive trial
outcome for non-progression.
METHODS
Study Design and Participants
Assessing Very Early Rheumatoid arthritis
Treatment (AVERT) was a phase 3b, random-
ized, active-controlled, 24-month trial in
patients with early RA (ClinicalTrials.gov iden-
tifier: NCT01142726) [8]. The trial included a
12-month, double-blind treatment period in
which patients received abatacept plus
methotrexate (MTX), abatacept monotherapy
or MTX alone (supplementary Fig. 1). Subcuta-
neous abatacept was administered at 125 mg/
week. MTX was titrated to 15–20 mg/week
within 6–8 weeks. The study design and results
have been described previously [8, 9]. The
AVERT study protocol was approved by the
Institutional Review Board or Independent
Ethics Committee at each site. All patients
provided written informed consent and the
study was performed in accordance with the
Declaration of Helsinki.
Contrast-enhanced 1.5-T MRIs of the clini-
cally most active hand and wrist were per-
formed [9]. Inflammation (synovitis and
osteitis) and erosions were scored at baseline,
and at months 6 and 12 by two independent
central radiologists (Charles Peterfy and Yan
Chen of Spire Sciences) blinded to treatment
arm and chronological order, using the Out-
come Measures in Rheumatology Clinical Trials
(OMERACT) RA MRI Score (RAMRIS) method
[10]. The scores of the two readers were
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averaged and the top 5% of discrepancies were
adjudicated by consensus review [9].
MRI Inflammation Thresholds Analysis
and Structural Damage Progression
MRI data were pooled from all three treatment
arms for this post hoc analysis. Patients were
stratified into two risk subgroups (less and more
severe inflammation) based on MRI inflamma-
tion scores at the start of the observation period.
The thresholds for less severe inflammation
(based on preliminary reported levels) were: B 3
for synovitis (total score 21), B 3 for osteitis
(total score 69) and B 9 when combined. For
combined total inflammation scores, osteitis
was double-weighted due to its greater ability in
multivariate analysis to predict structural dam-
age progression and its greater effect on subse-
quent erosion development compared with
synovitis, as assessed by radiography and MRI
[7, 11]. Structural damage progression was
defined as erosion change from baseline [ 0.5
(OMERACT-RAMRIS erosion score scale for each
bone: 0–10; range of scores: 0–230) [12] and
greater than the smallest detectable change
(SDC) (SDC value was 2.29) [9]. In order to
provide a comprehensive analysis, structural
damage progression was analyzed using MRI
inflammation scores at various time points: 0–-
12 months by MRI scores at baseline, and 6–-
12 months by MRI scores at month 6.
Statistical Analyses
Risks of progression (erosion change from
baseline [ 0.5 and [ SDC) were compared
between subgroups and treatment groups using
baseline Disease Activity Score in 28 joints [C-
reactive protein; DAS28 (CRP)]-adjusted logistic
models. Odds ratios and related P values were
reported.
The linear relationship between unadjusted
predicted probability of progression and erosion
score ([ 0.5) at baseline was explored (‘as-ob-
served’ analysis).
RESULTS
Patient Disposition and Baseline
Demographic Data
A total of 351 patients with early RA were ran-
domized, treated and had MRI data at baseline
[9]. Of these patients, 276 (78.6%) and 235
(67.0%) also had MRI data available at month 6
and month 12, respectively. Baseline demo-
graphic data and clinical characteristics for the
overall trial population [8] and MRI population
[9] have been reported previously. Briefly,
patients were anti-cyclic citrullinated peptide-2
positive, had a mean (SD) age of 47.0 (12.6)
years and symptom duration of 0.56 (0.50)
years, with 77.8% being female [8]. Patients had
highly active disease [mean (SD) tender joint
count of 13.6 (7.7) and swollen joint count of
11.1 (7.1)] with indicators of poor prognosis
(rheumatoid factor positivity: 95.2%; mean
CRP: 17.5 mg/L).
MRI Inflammation Thresholds
and Structural Damage Progression
For the overall population, when adjusted for
baseline DAS28 (CRP), the risks of structural
damage progression (defined as[0.5 or[ SDC)
at follow-up was significantly lower in the sub-
group with less versus more severe inflamma-
tion at baseline for all comparisons (P value
range =\0.001–0.0459) (Fig. 1; supplementary
Fig. 2). Only total inflammation score was not
significantly associated with progression greater
than the SDC between month 6 and month 12,
where rates were very low (based on month 6
scores, P = 0.1284). In by-treatment analyses
[also adjusted for baseline DAS28 (CRP)],
patients with less severe inflammation at base-
line showed significantly less progression from
0 to 12 months than patients with more severe
inflammation in most comparisons across all
treatment groups (supplementary Tables 1 and
2). The above observations were similar when
data were not adjusted for clinical activity, as
determined by DAS28 (CRP) (supplementary
Tables 3 and 4).
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MRI Inflammation Threshold Analysis
The unadjusted probability of progression (de-
fined as[ 0.5) from baseline to month 12 was
lower among patients with less versus more
severe inflammation at baseline (Fig. 2a). The
unadjusted probability of progression from
month 6 to month 12 was lower among patients
with less versus more severe inflammation at
month 6 (Fig. 2b). Similar trends were seen for
the unadjusted log odds progression analysis
(supplementary Fig. 3).
Fig. 1 Percentage and baseline DAS28 (CRP)-adjusted
odds ratios of MRI structural progression ([ 0.5) in the
overall population from 0 to 12 months by MRI inflam-
mation scores (a synovitis, b osteitis and c total inflam-
mation) at baseline (‘as-observed’ population). *Total
inflammation is synovitis ? osteitis double-weighted. CI
confidence interval, DAS28 (CRP) disease activity score in
28 joints (C-reactive protein), MRI magnetic resonance
imaging
Fig. 2 Association between inflammation scores and
unadjusted predicted probability of MRI structural pro-
gression (‘as-observed’ population). a Baseline inflamma-
tion scores and MRI progression (defined as change from 0
to 12 months in erosion score[ 0.5); vertical dotted lines
denote osteitis/synovitis score B 3 or total inflammation
score B 9 at baseline;.b Month 6 inflammation scores and
MRI progression (defined as change from 6 to 12 months
in erosion score[ 0.5); vertical dotted lines denote
osteitis/synovitis score B 3 or total inflammation score
B 9 at month 6. MRI magnetic resonance imaging
c
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DISCUSSION
This analysis established that lower levels of
MRI inflammation below the predefined
thresholds [B 3 for synovitis, B 3 for osteitis
and B 9 (osteitis double-weighted) when com-
bined into a total inflammation score] were
associated with a very low risk of MRI-detected,
baseline DAS28 (CRP)-adjusted structural dam-
age progression.
MRI is increasingly being used as an outcome
measure in RA clinical trials, usually in patients
with at least moderate disease activity. Moller-
Bisgaard et al. recently reported a randomized
clinical trial (IMAGINE-RA) targeting the
absence of MRI osteitis versus a clinical treat-to-
target approach in patients with RA in clinical
remission; no improvement of remission or
radiographic progression rates versus the con-
ventional strategy were observed [13]. However,
the IMAGINE-RA trial contrasts with the current
study with regard to trial design, baseline level
of disease and patient populations. For exam-
ple, in the current study, baseline mean DAS28-
CRP score [8] ranged from 5.3 to 5.5 and osteitis
scores ranged from 2.5 to 5.1, whereas in IMA-
GINE-RA, baseline median DAS28-CRP and MRI
osteitis scores were 1.9/2.0 and 2.0/2.0 (for both
arms, respectively) [13]. Furthermore, the IMA-
GINE-RA study targeted absence of osteitis,
whereas the present study investigates a com-
bined osteitis and synovitis target. Conse-
quently, future trials with treat-to-target
endpoints could benefit from including com-
bined MRI thresholds as a primary study out-
come measure for joint inflammation, thereby
enabling the identification of individuals with a
significant burden of inflammatory disease.
However, very little is currently known about
what level of inflammation may be deemed
acceptable (i.e., suggesting that the risk of sub-
sequent damage is low). Subsequently, there
will be a need to translate these findings into a
readily usable score for routine clinical use.
Inflammation score assessments, such as those
presented here, may complement standard
descriptive or clinical assessments and be used
to assess treatment efficacy and to improve the
efficacy of clinical studies. Treatment with an
effective treat-to-target strategy has been shown
to decrease MRI inflammation scores at 6 and
12 months, and has been associated with sig-
nificant reductions in clinical disease activity
and an absence of structural damage progres-
sion at 12 months [14].
The work reported here validates inflamma-
tory thresholds defined in earlier research using
golimumab trial data: data from the GO-
BEFORE trial were used to develop the thresh-
olds, while GO-FORWARD data were used for
validation [7]. The current validation was
achieved despite differences across the trial
populations: patients in the GO-BEFORE trial
were MTX-naı¨ve (as in AVERT) [8, 15], whereas
those in GO-FORWARD had an inadequate
response to MTX [16]. Differences between the
golimumab and AVERT trials also included the
drug and treatment regimens [8, 15, 16], and
patients in AVERT had early RA (persistent
symptoms for B 2 years) [8], whereas those in
the golimumab trials had a longer-standing
disease [15, 16].
In a GO-FORWARD validation analysis, 4.7%
of patients with less severe total inflammation
(i.e., no greater than the threshold of 9) versus
29.6% of patients with more severe total
inflammation (i.e., greater than the threshold of
9) at month 6 had structural damage progres-
sion between months 6 and 12 (progression
defined as [ 0.5; odds ratio: 0.11) [7]. In the
current analysis, these figures were 16.0% with
less severe versus 32.5% with more severe total
inflammation [baseline DAS28 (CRP)-adjusted
odds ratio: 0.41]. Overall, progression rates were
higher in the current study compared with the
golimumab analyses, likely due to the selection
of only patients who were seropositive and had
highly active disease. To identify an appropriate
cut-off for change in MRI, an erosion change of
[0.5, which has been described as a good dis-
criminator of radiography-detected structural
progression [12], and SDC, which has been
reported to be less variable and enable smaller
differences in disease progression to be detected
[17], were used in this study. Despite these dif-
ferences in overall rates of structural damage
progression, our analysis supports previous evi-
dence that a low MRI inflammation score is
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associated with an approximately 80% lower
odds of structural damage progression.
In a GO-FORWARD validation analysis of the
defined thresholds for synovitis and osteitis,
respectively, 7.8% and 9.0% of patients with
less severe inflammation (i.e., no greater than
the thresholds of 3) at month 6 had structural
damage progression by month 12 [7]. In the
current analysis, these figures were 11.1% and
18.0%, respectively. The importance of MRI
inflammation thresholds regarding subsequent
radiographic progression has been documented
in previous studies [6, 11, 12, 18, 19].
Strengths of the current analysis include the
large trial size and the well-defined study pop-
ulation of MTX-naı¨ve, anti-cyclic citrullinated
peptide-positive patients with highly active,
early RA. This research also validates earlier
work in a distinct patient population treated
with a different agent.
Limitations of this analysis, which should be
considered when interpreting data, include
that, as the study focused on patients with
highly active early RA, the findings may not be
generalizable to other populations. The work is
also a post hoc analysis, with inherent limita-
tions, such as the thresholds described here
were not tested in the trial as a pre-specified
outcome measure and the relationships
between probability of progression and erosion
score were from ‘as-observed’ analyses. Radio-
graphic data were not available for this study;
however, short-term changes in MRI-detected
inflammation have been found to predict long-
term changes on subsequent radiography in RA
[20]. A limitation of defining low inflammatory
thresholds is that older patients and those with
osteoarthritis may have detectable inflamma-
tion by MRI [21]. However, patients would be
very unlikely to have scores above the threshold
used in this current study; for example, the
median synovitis score reported was 0.5 with an
inter-quartile range of 0–2, suggesting 75% of
patients from in the general population had
scores B 2 [21].
Further research is needed to determine
whether these and other thresholds, such as
those including tenosynovitis, on MRI are
applicable and optimal across different popula-
tions of patients with RA and during treatment
with DMARDs with different mechanisms of
action. Additionally, an investigation into
whether achievement of low MRI-detected
inflammation is associated with optimization of
patient-reported outcomes would be very timely
[21, 22] and could form the basis for a logical
next study.
CONCLUSION
In summary, this post hoc analysis indicates
that the achievement of target levels of
inflammation in patients with early RA is asso-
ciated with a very low risk of structural damage
progression. These post hoc data provide further
support for the value of measuring joint
inflammation and damage using objective
imaging techniques, and indicate that such
measures may have the potential to be used as
trial endpoints in certain patient populations
and to contribute to personalized RA treatment
in the future.
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